440 related articles for article (PubMed ID: 16539393)
1. Inhibition of hepatitis B virus (HBV) replication by pyrimidines bearing an acyclic moiety: effect on wild-type and mutant HBV.
Semaine W; Johar M; Tyrrell DL; Kumar R; Agrawal B
J Med Chem; 2006 Mar; 49(6):2049-54. PubMed ID: 16539393
[TBL] [Abstract][Full Text] [Related]
2. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
[TBL] [Abstract][Full Text] [Related]
3. Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.
Srivastav NC; Shakya N; Mak M; Agrawal B; Tyrrell DL; Kumar R
J Med Chem; 2010 Oct; 53(19):7156-66. PubMed ID: 20857959
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and anti-HIV and anti-HBV activities of 2'-fluoro-2', 3'-unsaturated L-nucleosides.
Lee K; Choi Y; Gullen E; Schlueter-Wirtz S; Schinazi RF; Cheng YC; Chu CK
J Med Chem; 1999 Apr; 42(7):1320-8. PubMed ID: 10197975
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
Zoulim F
Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiviral screening of some thieno[2,3-d]pyrimidine nucleosides.
Rashad AE; Ali MA
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):17-28. PubMed ID: 16440982
[TBL] [Abstract][Full Text] [Related]
7. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
8. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
[TBL] [Abstract][Full Text] [Related]
9. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
10. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Billioud G; Pichoud C; Puerstinger G; Neyts J; Zoulim F
Antiviral Res; 2011 Nov; 92(2):271-6. PubMed ID: 21871497
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo- and pyrrolo[2,3-d]pyrimidine nucleosides.
Janeba Z; Balzarini J; Andrei G; Snoeck R; De Clercq E; Robins MJ
J Med Chem; 2005 Jul; 48(14):4690-6. PubMed ID: 16000005
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel 5-substituted acyclic pyrimidine nucleosides as potent and selective inhibitors of hepatitis B virus.
Kumar R; Nath M; Tyrrell DL
J Med Chem; 2002 May; 45(10):2032-40. PubMed ID: 11985471
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi.
Teng X; Xu WZ; Hao ML; Fang Y; Zhao YX; Chen SJ; Li D; Gu HX
J Virol Methods; 2010 Sep; 168(1-2):6-12. PubMed ID: 20403386
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in-vitro anti-hepatitis-B virus activity of 6H-[1]benzothiopyrano[4,3-b] quinolin-10-ols.
Jia W; Zhao Y; Li R; Wu Y; Li Z; Gong P
Arch Pharm (Weinheim); 2009 Sep; 342(9):507-12. PubMed ID: 19637181
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
Srivastav NC; Mak M; Agrawal B; Tyrrell DL; Kumar R
Bioorg Med Chem Lett; 2010 Nov; 20(22):6790-3. PubMed ID: 20863701
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-HSV activity of new N1-acyclic C4 and C6-disubstituted pyrazolo[3,4-d]pyrimidine nucleosides.
Moukha-chafiq O; Taha ML; Mouna A
Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1107-10. PubMed ID: 18058546
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ
J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991
[TBL] [Abstract][Full Text] [Related]
18. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives.
Xu B; Huang Z; Liu C; Cai Z; Pan W; Cao P; Hao X; Liang G
Bioorg Med Chem; 2009 Apr; 17(8):3118-25. PubMed ID: 19307124
[TBL] [Abstract][Full Text] [Related]
20. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
Yim HJ; Hussain M; Liu Y; Wong SN; Fung SK; Lok AS
Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
